CM
NBIX icon

Caption Management’s Neurocrine Biosciences NBIX Stock Holding History

Caption Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.95M Sell
30,000
-5,000
-14% -$663K 0.02% 601
2025
Q4 		$4.96M Buy
35,000
+5,000
+17% +$724K 0.03% 520
2025
Q3 		$4.21M Hold
30,000
– – 0.03% 560
2025
Q2 		$3.77M Buy
+30,000
New +$3.44M 0.04% 490
2024
Q4 		– Sell
-40,100
Closed -$4.62M – 1705
2024
Q3 		$4.62M Buy
40,100
+25,100
+167% +$3.44M 0.07% 319
2024
Q2 		$2.07M Buy
+15,000
New +$2.06M 0.03% 466
2024
Q1 		– Sell
-55,000
Closed -$7.25M – 1527
2023
Q4 		$7.25M Sell
55,000
-5,000
-8% -$576K 0.1% 247
2023
Q3 		$6.75M Buy
60,000
+15,000
+33% +$1.58M 0.1% 244
2023
Q2 		$4.24M Buy
45,000
+15,000
+50% +$1.47M 0.08% 319
2023
Q1 		$3.04M Buy
30,000
+5,000
+20% +$520K 0.06% 342
2022
Q4 		$2.99M Sell
25,000
-3,600
-13% -$422K 0.05% 451
2022
Q3 		$3.04M Sell
28,600
-26,400
-48% -$2.68M 0.04% 502
2022
Q2 		$5.36M Sell
55,000
-35,000
-39% -$3.23M 0.07% 326
2022
Q1 		$8.44M Sell
90,000
-20,000
-18% -$1.69M 0.1% 272
2021
Q4 		$9.37M Buy
110,000
+20,000
+22% +$1.84M 0.11% 250
2021
Q3 		$8.63M Buy
90,000
+30,000
+50% +$2.83M 0.1% 267
2021
Q2 		$5.84M Buy
+60,000
New +$5.75M 0.08% 335
2020
Q4 		– Sell
-30,000
Closed -$2.89M – 1169
2020
Q3 		$2.89M Hold
30,000
– – 0.07% 335
2020
Q2 		$3.66M Sell
30,000
-40,000
-57% -$4.42M 0.12% 226
2020
Q1 		$6.06M Buy
70,000
+45,000
+180% +$4.4M 0.34% 71
2019
Q4 		$2.69M Buy
+25,000
New +$2.62M 0.09% 305
2019
Q3 		– Sell
-30,000
Closed -$2.53M – 830
2019
Q2 		$2.53M Buy
30,000
+7,500
+33% +$616K 0.13% 212
2019
Q1 		$1.98M Buy
+22,500
New +$1.88M 0.11% 240

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's NBIX Position: Q1 2026 in Review

Caption Management opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 8,900 shares worth $1.17M. The stake represents 0.01% of the portfolio and ranks #974 among its holdings. This is a return to the name: Caption Management previously reported a position in NBIX as recently as Q1 2025.

Caption Management first reported a position in NBIX in Q1 2019 and has held it in 17 quarters since. The position peaked at $14.5M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Caption Management held 8,900 shares of Neurocrine Biosciences worth $1.17M as of Q1 2026.
  • Neurocrine Biosciences was a new Caption Management position in Q1 2026.
  • Neurocrine Biosciences made up 0.01% of Caption Management's portfolio in Q1 2026, its #974 holding.
  • Caption Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 17 quarters since.
  • Caption Management's Neurocrine Biosciences position peaked at $14.5M in Q1 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.